Skip to main content

Table 1 Selected patients’ characteristics

From: Promoter hypermethylation and silencing of tissue factor pathway inhibitor-2 in oral squamous cell carcinoma

(a) TFPI-2 methylation level by qMSP

 

n

(%)

Mean

SD

Median

IQR

Gender

      

 Male

110

(100)

13.64

13.05

8.94

21.06

Pathological Stage

      

 Normal

24

(21.8)

4.45

7.51

1.79

1.62

 I

20

(18.2)

16.23

12.97

13.87

16.71

 II

12

(10.9)

12.96

12.46

6.96

23.95

 III

25

(22.7)

17.19

13.62

16.86

23.15

 IV

29

(26.4)

16.67

13.60

16.64

19.61

Cancer Site

      

 Buccal

36

(41.9)

17.05

12.46

15.95

18.90

 Tongue

50

(58.1)

15.59

13.71

11.66

22.63

(b) TFPI-2 methylation level by pyrosequencing

 

n

(%)

Mean

SD

Median

IQR

Gender

      

 Male

60

(100)

18.80

14.99

15.58

23.79

Pathological Stage

      

 Normal

11

(18.3)

4.43

1.91

3.82

2.94

 I

15

(25.0)

20.35

12.19

18.26

23.14

 II

12

(20.0)

16.21

9.48

12.17

12.97

 III

14

(23.3)

21.63

16.08

21.03

28.34

 IV

8

(13.3)

34.63

18.06

33.10

23.50

Cancer Site

      

 Buccal

19

(38.8)

29.70

14.41

28.12

16.07

 Tongue

30

(61.2)

17.18

12.96

13.86

20.82

  1. SD: standard deviation; IQR: interquartile range.